Abstract 549P
Background
Interstitial pneumonia (IP) or interstitial lung abnormalities (ILA) is a risk factor for drug-induced interstitial lung disease (D-ILD) in immunotherapy. We usually evaluate interstitial pneumonia by CT findings without histopathological findings. We aimed to evaluate whether histopathological findings of the background lung in surgical specimens is correlated with development of D-ILD by immunotherapy in patients with postoperative recurrence.
Methods
Patients who were treated with immunotherapy or immunochemotherapy for first-line treatment of non-small cell lung cancer for postoperative recurrence from April 2017 to February 2023 were included. We retrospectively compared between characteristics of patients with and without D-ILD, including CT findings and histopathological findings of the background lung in surgical specimens.
Results
Among 32 included patients, we evaluated 27 patients whose surgical specimens were available. The median age was 72 years old, and 20 patients (74.1%) were male. Twelve patients (44.4%) had ILA on CT, and five patients (18.5%) had IP with usual interstitial pneumonia (UIP) pattern (two patients with UIP, one patient with probable UIP, and two patients with indeterminate for UIP) on pathology. Five patients (18.5%) developed D-ILD, including two patients with CTCAE grade 1, two patients with grade 2, and one patient with grade 5. Patients with D-ILD were significantly more likely to have ILA on CT than those without D-ILD (5/5[100%] vs. 7/22[31.8%], p<0.01). Although there was no significant difference, two of the patients with D-ILD had UIP pattern on pathology as compared with three of those without D-ILD (2/5[40%] vs. 3/22[13.6%] p=0.22). Four patients had both ILA on CT and UIP pattern on pathology, and two (50%) of these cases developed D-ILD.
Conclusions
In addition to chest CT findings, histopathological findings of the background lung in surgical specimens may be useful as predictors of D-ILD in immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Tanaka: Financial Interests, Personal, Speaker, Consultant, Advisor: Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo; Financial Interests, Personal, Royalties: Bunkodo Co., Ltd., Gakken Inc. N. Katsurada: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K. T. Nagano: Financial Interests, Personal, Invited Speaker: AstraZeneca K.K. M. Yamamoto: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd. M. Tachihara: Financial Interests, Personal, Invited Speaker: Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd, AstraZeneca K.K, MSD K.K., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo, Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract